{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T22:59:03Z","timestamp":1785106743466,"version":"3.55.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Antibiot"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41429-026-00930-2","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T03:06:52Z","timestamp":1779851212000},"page":"533-541","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Combined effect of eravacycline and omadacycline with other antimicrobial agents against Acinetobacter Baumannii"],"prefix":"10.1038","volume":"79","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-9009-4558","authenticated-orcid":false,"given":"\u00d6zlem","family":"Erko\u00e7 G\u00fclery\u00fcz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8571-7849","authenticated-orcid":false,"given":"G\u00fclhan","family":"Vardar \u00dcnl\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"930_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.4161\/viru.19700","volume":"3","author":"A Howard","year":"2012","unstructured":"Howard A, O\u2019Donoghue M, Feeney A, Sleator RD. Acinetobacter baumannii: an emerging opportunistic pathogen. Virulence. 2012;3:243\u201350.","journal-title":"Virulence"},{"key":"930_CR2","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/antibiotics9030119","volume":"9","author":"C Ayoub Moubareck","year":"2020","unstructured":"Ayoub Moubareck C, Hammoudi Halat D. Insights into Acinetobacter baumannii: a review of microbiological, virulence, and resistance traits in a threatening nosocomial pathogen. Antibiotics. 2020;9:119.","journal-title":"Antibiotics"},{"key":"930_CR3","doi-asserted-by":"publisher","first-page":"6987","DOI":"10.1007\/s11033-021-06690-6","volume":"48","author":"S Ibrahim","year":"2021","unstructured":"Ibrahim S, Al-Saryi N, Al-Kadmy IMS, Aziz SN. Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals. Mol Biol Rep. 2021;48:6987\u201398.","journal-title":"Mol Biol Rep"},{"key":"930_CR4","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1086\/500202","volume":"42","author":"PE Fournier","year":"2006","unstructured":"Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006;42:692\u20139.","journal-title":"Clin Infect Dis"},{"key":"930_CR5","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","volume":"18","author":"AP Magiorakos","year":"2012","unstructured":"Magiorakos AP, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268\u201381.","journal-title":"Clin Microbiol Infect"},{"key":"930_CR6","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1086\/528867","volume":"46","author":"ME Falagas","year":"2008","unstructured":"Falagas ME, Karageorgopoulos DE. Pandrug resistance (PDR), extensive drug resistance (XDR), and multidrug resistance (MDR) among Gram-negative bacilli: need for international harmonization in terminology. Clin Infect Dis. 2008;46:1121\u20132.","journal-title":"Clin Infect Dis"},{"key":"930_CR7","first-page":"1","volume":"29","author":"\u015e S\u00fcer","year":"2024","unstructured":"S\u00fcer \u015e, et al. Diren\u00e7li gram-negatif bakteri infeksiyonlar\u0131n\u0131n y\u00f6netiminde s\u0131k kar\u015f\u0131la\u015f\u0131lan sorunlar ve \u00e7\u00f6z\u00fcm \u00f6nerileri: Klinik prati\u011fe y\u00f6nelik uzman g\u00f6r\u00fc\u015f\u00fc. FLORA. 2024;29:1\u201324.","journal-title":"FLORA"},{"key":"930_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.2174\/138161213804070285","volume":"19","author":"BA Evans","year":"2013","unstructured":"Evans BA, Hamouda A, Amyes SG. The rise of carbapenem-resistant Acinetobacter baumannii. Curr Pharm Des. 2013;19:223\u201338.","journal-title":"Curr Pharm Des"},{"key":"930_CR9","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jhm.2477","volume":"11","author":"MD Zilberberg","year":"2016","unstructured":"Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med. 2016;11:21\u201326.","journal-title":"J Hosp Med"},{"key":"930_CR10","doi-asserted-by":"publisher","DOI":"10.1128\/Spectrum.01010-21","volume":"9","author":"J Jo","year":"2021","unstructured":"Jo J, Ko KS. Tigecycline heteroresistance and resistance mechanism in clinical isolates of Acinetobacter baumannii. Microbiol Spectr. 2021;9:e0101021.","journal-title":"Microbiol Spectr"},{"key":"930_CR11","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1093\/cid\/civ048","volume":"60","author":"ZA Qureshi","year":"2015","unstructured":"Qureshi ZA, et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis. 2015;60:1295\u2013303.","journal-title":"Clin Infect Dis"},{"key":"930_CR12","unstructured":"Clinical and Laboratory Standards Institute. M100 Performance Standards for Antimicrobial Susceptibility Testing. 2024;Clinical and Laboratory Standards Institute."},{"key":"930_CR13","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1007\/s10096-019-03590-3","volume":"38","author":"YR Lee","year":"2019","unstructured":"Lee YR, Burton CE. Eravacycline, a newly approved fluorocycline. Eur J Clin Microbiol Infect Dis. 2019;38:1787\u201394.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"930_CR14","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1128\/AAC.04809-14","volume":"59","author":"M Abdallah","year":"2015","unstructured":"Abdallah M, et al. Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City. Antimicrob Agents Chemother. 2015;59:1802\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"930_CR15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa071","volume":"7","author":"S Alosaimy","year":"2020","unstructured":"Alosaimy S, et al. Early experience with eravacycline for complicated infections. Open Forum Infect Dis. 2020;7:ofaa071.","journal-title":"Open Forum Infect Dis"},{"key":"930_CR16","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-020-01257-4","volume":"80","author":"GG Zhanel","year":"2020","unstructured":"Zhanel GG, et al. Omadacycline: a novel oral and intravenous aminomethylcycline antibiotic agent. Drugs. 2020;80:285\u2013313.","journal-title":"Drugs"},{"key":"930_CR17","first-page":"1715","volume":"11","author":"T Morrisette","year":"2022","unstructured":"Morrisette T, et al. Real-world, multicenter case series of patients treated with oral omadacycline for resistant gram-negative pathogens. Infect Dis Ther. 2022;11:1715\u201323.","journal-title":"Infect Dis Ther"},{"key":"930_CR18","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: Thirty-first Edition M100S."},{"key":"930_CR19","unstructured":"CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically. 12th ed. CLSI standard M07. 2024;Clinical and Laboratory Standards Institute."},{"key":"930_CR20","unstructured":"Eliopoulos G, Moellering RC. Antimicrobial combinations. In: Lorian V, ed. Antibiotics in Laboratory Medicine. 4th ed. Baltimore: Williams & Wilkins; 1996:330\u201396."},{"key":"930_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","volume":"52","author":"FC Odds","year":"2003","unstructured":"Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother. 2003;52:1 https:\/\/doi.org\/10.1093\/jac\/dkg301.","journal-title":"J Antimicrob Chemother"},{"key":"930_CR22","doi-asserted-by":"publisher","DOI":"10.1093\/jambio\/lxae090","volume":"135","author":"U Yilmaz","year":"2024","unstructured":"Yilmaz U, Co\u015fkun AG, \u00d6zel Y, \u00dcnl\u00fc M, Vardar-\u00dcnl\u00fc G. Synergistic interactions of essential oil components with antibiotics against multidrug-resistant Corynebacterium striatum. J Appl Microbiol. 2024;135:lxae090. https:\/\/doi.org\/10.1093\/jambio\/lxae090.","journal-title":"J Appl Microbiol"},{"key":"930_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41426-018-0038-9","volume":"7","author":"R Xie","year":"2018","unstructured":"Xie R, Zhang XD, Zhao Q, Peng B, Zheng J. Analysis of global prevalence of antibiotic resistance in Acinetobacter baumannii infections disclosed a faster increase in OECD countries. Emerg Microbes Infect. 2018;7:31.","journal-title":"Emerg Microbes Infect"},{"key":"930_CR24","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.burns.2019.07.006","volume":"45","author":"WG Lima","year":"2019","unstructured":"Lima WG, Silva Alves GC, Sanches C, Fernandes SO, de Paiva MC. Carbapenem-resistant Acinetobacter baumannii in patients with burn injury: a systematic review and meta-analysis. Burns. 2019;45:1495\u2013508.","journal-title":"Burns"},{"key":"930_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13756-020-00750-5","volume":"9","author":"O Ayobami","year":"2020","unstructured":"Ayobami O, Willrich N, Suwono B, Eckmanns T, Markwart R. The epidemiology of carbapenem-non-susceptible Acinetobacter species in Europe: analysis of EARS-Net data from 2013 to 2017. Antimicrob Resist Infect Control. 2020;9:1\u201310.","journal-title":"Antimicrob Resist Infect Control"},{"key":"930_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/CMR.00042-16","volume":"30","author":"LY Hsu","year":"2017","unstructured":"Hsu LY, et al. Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev. 2017;30:1\u201322.","journal-title":"Clin Microbiol Rev"},{"key":"930_CR27","unstructured":"European Committee on Antimicrobial Susceptibility Testing (EUCAST). Breakpoint tables for interpretation of MICs and zone diameters. Version 13.0. Published January 2024. Available at: https:\/\/www.eucast.org. Accessed January 2, 2025."},{"key":"930_CR28","first-page":"12","volume":"26","author":"Oral \u00d6nc\u00fcl","year":"2012","unstructured":"\u00d6nc\u00fcl O. Kolistin: Endikasyon ve klinik kullan\u0131m\u0131. ANKEM Derg. 2012;26:12\u201318.","journal-title":"ANKEM Derg"},{"key":"930_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13756-024-01376-7","volume":"13","author":"N Bostanghadiri","year":"2024","unstructured":"Bostanghadiri N, Narimisa N, Mirshekar M, Dadgar-Zankbar L, Taki E, Navidifar T, et al. Prevalence of colistin resistance in clinical isolates of Acinetobacter baumannii: a systematic review and meta-analysis. Antimicrob Resist Infect Control. 2024;13:24 https:\/\/doi.org\/10.1186\/s13756-024-01376-7.","journal-title":"Antimicrob Resist Infect Control"},{"key":"930_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2023.116006","volume":"107","author":"R Rahul","year":"2023","unstructured":"Rahul R, Maheswary D, Damodaran N, Leela KV. Eravacycline: Synergistic activity with other antimicrobials in carbapenem-resistant isolates of Escherichia coli and Acinetobacter baumannii. Diagn Microbiol Infect Dis. 2023;107:116006.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"930_CR31","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.3390\/microorganisms12071353","volume":"12","author":"J Halim","year":"2024","unstructured":"Halim J, et al. Combinations of antibiotics effective against extensively- and pandrug-resistant Acinetobacter baumannii patient isolates. Microorganisms. 2024;12:1353.","journal-title":"Microorganisms"},{"key":"930_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00542-22","volume":"10","author":"T Abbey","year":"2022","unstructured":"Abbey T, Vialichka A, Jurkovic M, Biagi M, Wenzler E. Activity of omadacycline alone and in combination against carbapenem-nonsusceptible Acinetobacter baumannii with varying minocycline susceptibility. Microbiol Spectr. 2022;10:e0054222.","journal-title":"Microbiol Spectr"},{"key":"930_CR33","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2018-0127","volume":"5","author":"S Vijayakumar","year":"2019","unstructured":"Vijayakumar S, Biswas I, Veeraraghavan B. Accurate identification of clinically important Acinetobacter spp.: an update. Future Sci OA. 2019;5:FSO395. https:\/\/doi.org\/10.2144\/fsoa-2018-0127.","journal-title":"Future Sci OA"},{"key":"930_CR34","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1080\/1120009X.2021.2005755","volume":"34","author":"T Yin","year":"2022","unstructured":"Yin T, et al. ACTION study group. In vitro and in vivo comparison of eravacycline- and tigecycline-based combination therapies for tigecycline-resistant Acinetobacter baumannii. J Chemother. 2022;34:166\u201372.","journal-title":"J Chemother"},{"key":"930_CR35","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","volume":"76","author":"GG Zhanel","year":"2016","unstructured":"Zhanel GG, et al. Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs. 2016;76:567\u201388.","journal-title":"Drugs"},{"key":"930_CR36","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.diagmicrobio.2017.12.013","volume":"91","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Baxter MR, Adam HJ, Sutcliffe J, Karlowsky JA. In vitro activity of eravacycline against 2213 Gram-negative and 2424 Gram-positive bacterial pathogens isolated in Canadian hospital laboratories: CANWARD surveillance study 2014-2015. Diagn Microbiol Infect Dis. 2018;91:55\u201362.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"930_CR37","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.jgar.2021.09.011","volume":"27","author":"MA Pfaller","year":"2021","unstructured":"Pfaller MA, Huband MD, Shortridge D, Flamm RK. Surveillance of omadacycline activity tested against clinical isolates from the USA: report from the SENTRY Antimicrobial Surveillance Program, 2019. J Glob Antimicrob Resist. 2021;27:337\u201351.","journal-title":"J Glob Antimicrob Resist"},{"key":"930_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.10.010","volume":"55","author":"H Seifert","year":"2020","unstructured":"Seifert H, Stefanik D, Olesky M, Higgins PG. In vitro activity of the novel fluorocycline TP-6076 against carbapenem-resistant Acinetobacter baumannii. Int J Antimicrob Agents. 2020;55:105829.","journal-title":"Int J Antimicrob Agents"},{"key":"930_CR39","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1007\/s10096-020-03877-w","volume":"39","author":"D Dong","year":"2020","unstructured":"Dong D, et al. In vitro activity of omadacycline against pathogens isolated from Mainland China during 2017-2018. Eur J Clin Microbiol Infect Dis. 2020;39:1559\u201372.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"930_CR40","first-page":"210","volume":"45","author":"G Meletis","year":"2022","unstructured":"Meletis G, et al. In vitro activity of eravacycline and cefoperazone\/sulbactam against extensively drug-resistant and pan-drug-resistant Acinetobacter baumannii isolates from a tertiary hospital in Greece. N Microbiol. 2022;45:210\u20132.","journal-title":"N Microbiol"},{"key":"930_CR41","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jmii.2021.08.012","volume":"55","author":"PY Liu","year":"2022","unstructured":"Liu PY, et al. In vitro activity of cefiderocol, cefepime\/enmetazobactam, cefepime\/zidebactam, eravacycline, omadacycline, and other comparative agents against carbapenem-non-susceptible Pseudomonas aeruginosa and Acinetobacter baumannii isolates associated with bloodstream infection in Taiwan between 2018-2020. J Microbiol Immunol Infect. 2022;55:888\u201395.","journal-title":"J Microbiol Immunol Infect"},{"key":"930_CR42","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.jgar.2022.05.020","volume":"30","author":"Y Li","year":"2022","unstructured":"Li Y, Cui L, Xue F, Wang Q, Zheng B. Synergism of eravacycline combined with other antimicrobial agents against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii. J Glob Antimicrob Resist. 2022;30:56\u201359.","journal-title":"J Glob Antimicrob Resist"},{"key":"930_CR43","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.jgar.2023.04.017","volume":"33","author":"S Hawser","year":"2023","unstructured":"Hawser S, et al. In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020. J Glob Antimicrob Resist. 2023;33:304\u201320.","journal-title":"J Glob Antimicrob Resist"},{"key":"930_CR44","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.2147\/IDR.S396910","volume":"16","author":"X Zou","year":"2023","unstructured":"Zou X, et al. Antibacterial activity of eravacycline against carbapenem-resistant Gram-negative isolates in China: an in vitro study. Infect Drug Resist. 2023;16:2271\u20139.","journal-title":"Infect Drug Resist"},{"key":"930_CR45","unstructured":"Ataman M. Eravasiklinin tek ba\u015f\u0131na ve \u00e7e\u015fitli antibiyotiklerle kombinasyon halinde Acinetobacter baumannii su\u015flar\u0131na kar\u015f\u0131 in vitro antimikrobiyal etkinliklerinin ara\u015ft\u0131r\u0131lmas\u0131. [Doktora tezi]. \u0130stanbul: \u0130stanbul \u00dcniversitesi \/. Sa\u011fl\u0131k Bilimleri Enstit\u00fcs\u00fc;. 2023."},{"key":"930_CR46","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1007\/s10096-023-04583-z","volume":"42","author":"S Chandran","year":"2023","unstructured":"Chandran S, et al. Enhanced bacterial killing with a combination of sulbactam\/minocycline against dual carbapenemase-producing Acinetobacter baumannii. Eur J Clin Microbiol Infect Dis. 2023;42:645\u201351.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"930_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1417237","volume":"15","author":"X Chen","year":"2024","unstructured":"Chen X, et al. Comparison of antimicrobial activities and resistance mechanisms of eravacycline and tigecycline against clinical Acinetobacter baumannii isolates in China. Front Microbiol. 2024;15:1417237.","journal-title":"Front Microbiol"},{"key":"930_CR48","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1007\/s10096-023-04616-7","volume":"42","author":"I Galani","year":"2023","unstructured":"Galani I, et al. In vitro activities of omadacycline, eravacycline, cefiderocol, apramycin, and comparator antibiotics against Acinetobacter baumannii causing bloodstream infections in Greece, 2020-2021: A multicenter study. Eur J Clin Microbiol Infect Dis. 2023;42:843\u201352.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"930_CR49","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.1093\/jac\/dkae220","volume":"79","author":"R Jing","year":"2024","unstructured":"Jing R, et al. Establishment of epidemiological cut-off values for eravacycline against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii, and Staphylococcus aureus. J Antimicrob Chemother. 2024;79:2246\u201350.","journal-title":"J Antimicrob Chemother"}],"container-title":["The Journal of Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00930-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00930-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T22:01:47Z","timestamp":1785103307000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41429-026-00930-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":49,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["930"],"URL":"https:\/\/doi.org\/10.1038\/s41429-026-00930-2","relation":{},"ISSN":["0021-8820","1881-1469"],"issn-type":[{"value":"0021-8820","type":"print"},{"value":"1881-1469","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"27 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could appear to have influenced the work reported in this paper.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Ethical approval for this study was obtained from the Bal\u0131kesir University Health Sciences Non-Interventional Research Ethics Committee (Approval No: 2024\/117).","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}